Furthermore, emerging evidence in the therapy of obesity highlights the efficacy of newer pharmacological agents, specifically GLP-1 receptor agonists (GLP-1RAs), which significantly reduce body weight, BMI, and waist circumference in patients without diabetes mellitus. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.